Analysts expect that Bicycle Therapeutics Limited (NASDAQ:BCYC) will post $12.55 million in sales for the current fiscal quarter, Zacks reports. Three analysts have issued estimates for Bicycle Therapeutics’ earnings. The lowest sales estimate is $1.25 million and the highest is $30.00 million. The firm is scheduled to report its next quarterly earnings report on Monday, January 1st.
On average, analysts expect that Bicycle Therapeutics will report full year sales of $16.27 million for the current financial year, with estimates ranging from $5.00 million to $30.00 million. For the next fiscal year, analysts anticipate that the business will post sales of $6.00 million. Zacks’ sales calculations are a mean average based on a survey of research firms that that provide coverage for Bicycle Therapeutics.
Bicycle Therapeutics (NASDAQ:BCYC) last posted its quarterly earnings data on Tuesday, March 10th. The company reported ($0.25) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.52) by $0.27. Bicycle Therapeutics had a negative net margin of 221.78% and a negative return on equity of 56.13%. The business had revenue of $5.28 million during the quarter, compared to the consensus estimate of $0.80 million.
NASDAQ BCYC traded down $1.78 on Tuesday, reaching $12.77. 17,147 shares of the company’s stock traded hands, compared to its average volume of 26,439. The firm has a market cap of $203.50 million and a price-to-earnings ratio of -4.61. The stock has a 50 day moving average price of $13.74 and a 200-day moving average price of $10.67. Bicycle Therapeutics has a fifty-two week low of $6.24 and a fifty-two week high of $19.79.
An institutional investor recently bought a new position in Bicycle Therapeutics stock. Point72 Asset Management L.P. bought a new stake in shares of Bicycle Therapeutics Limited (NASDAQ:BCYC) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 382,499 shares of the company’s stock, valued at approximately $3,607,000. Point72 Asset Management L.P. owned 2.16% of Bicycle Therapeutics at the end of the most recent reporting period. 33.36% of the stock is owned by institutional investors.
Bicycle Therapeutics Company Profile
Bicycle Therapeutics Limited, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease.
Read More: Circuit Breakers
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Bicycle Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bicycle Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.